ClinicalTrials.Veeva

Menu

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

Lilly logo

Lilly

Status and phase

Not yet enrolling
Phase 2
Phase 1

Conditions

Immune Thrombocytopenia (ITP)

Treatments

Drug: Placebo
Drug: Pirtobrutinib

Study type

Interventional

Funder types

Industry

Identifiers

NCT06721013
J2N-MC-JZNZ (Other Identifier)
27294

Details and patient eligibility

About

The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo.

The study drug will be administered orally in participants with Primary Immune Thrombocytopenia (ITP). Blood tests will be performed to check how much pirtobrutinib gets into the bloodstream and how long it takes the body to eliminate it.

The study will last up to approximately 16 weeks for phase 1 dose-escalation and 28 weeks for phase 2 dose-optimization, excluding screening.

Enrollment

58 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Have a diagnosis of primary ITP, defined as isolated thrombocytopenia not associated with another known disease process
  • Have documented history of response, defined as 2 or more platelet counts greater than or equal to 50,000/microliter (μL), to at least 1 prior line of therapy. Splenectomy is considered a line of therapy
  • Have relapsed or treatment-resistant primary ITP, with no available therapies known to provide clinical benefit
  • Have a platelet count less than 30,000/μL on 2 occasions more than 5 days apart in the 15 days before randomization
  • Have adequate liver, renal, and hematologic functions as defined by a table
  • Are willing to follow contraception requirements

Exclusion criteria

  • Have a history of any thrombotic or embolic event within 12 months before screening
  • Had a transfusion with blood or blood products or plasmapheresis within 14 days (Phase 1) or within 28 days (Phase 2) of randomization
  • Have significant cardiovascular disease
  • Have a diagnosis or history of hematologic malignancy
  • Have hepatitis B virus (HBV) defined as positive for antigen of hepatitis B (HBsAg) or polymerase chain reaction (PCR) positive for HBV deoxyribonucleic acid (DNA)
  • Have hepatitis C virus (HCV) defined as positive for anti-HCV antibodies and PCR positive for HCV ribonucleic acid (RNA)

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Sequential Assignment

Masking

Double Blind

58 participants in 3 patient groups, including a placebo group

Pirtobrutinib Phase 1
Experimental group
Description:
Pirtobrutinib administered orally
Treatment:
Drug: Pirtobrutinib
Pirtobrutinib Phase 2
Experimental group
Description:
Pirtobrutinib administered orally
Treatment:
Drug: Pirtobrutinib
Placebo Phase 2
Placebo Comparator group
Description:
Placebo administered orally
Treatment:
Drug: Placebo

Trial contacts and locations

4

Loading...

Central trial contact

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems